109 related articles for article (PubMed ID: 22240842)
1. Pharmacokinetics and pharmacodynamics of KR-66223, a novel DPP-4 inhibitor.
Song JS; Lee KR; Kwon HJ; Rhee SD; Kim MS; Choi SH; Lee SH; Song IS; Ahn JH; Ahn SH; Bae MA
Drug Metab Pharmacokinet; 2012; 27(2):216-22. PubMed ID: 22240842
[TBL] [Abstract][Full Text] [Related]
2. Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods.
Liu D; Ma X; Liu Y; Zhou H; Shi C; Wu F; Jiang J; Hu P
Eur J Pharm Sci; 2016 Jun; 89():73-82. PubMed ID: 27108678
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
[TBL] [Abstract][Full Text] [Related]
4. ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus.
Jain MR; Joharapurkar AA; Kshirsagar SG; Patel VJ; Bahekar RH; Patel HV; Jadav PA; Patel PR; Desai RC
Br J Pharmacol; 2017 Jul; 174(14):2346-2357. PubMed ID: 28452143
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor.
Jain MR; Joharapurkar AA; Bahekar RH; Patel H; Jadav P; Kshirsagar SG; Patel VJ; Patel KN; Ramanathan VK; Patel PR; Desai RC
J Diabetes; 2015 Sep; 7(5):708-17. PubMed ID: 25327540
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
Fura A; Khanna A; Vyas V; Koplowitz B; Chang SY; Caporuscio C; Boulton DW; Christopher LJ; Chadwick KD; Hamann LG; Humphreys WG; Kirby M
Drug Metab Dispos; 2009 Jun; 37(6):1164-71. PubMed ID: 19251818
[TBL] [Abstract][Full Text] [Related]
7. Is the Inhibition of Dipeptidyl Peptidase-4 (DDP-4) Enzyme Route Dependent and/or Driven by High Peak Concentration?- Seeking Answers with ZYDPLA1, a Novel Long Acting DPP-4 Inhibitor, in a Rodent Model.
Patel H; Joharapurkar AA; Bahekar R; Patel P; Kshirsagar SG; Modi N; Ghoghari A; Patel VJ; Jain MR; Srinivas NR; Patel PR; Desai RC
Drug Res (Stuttg); 2017 Apr; 67(4):223-227. PubMed ID: 28158894
[TBL] [Abstract][Full Text] [Related]
8. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
[TBL] [Abstract][Full Text] [Related]
9. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Yoshida T; Akahoshi F; Sakashita H; Kitajima H; Nakamura M; Sonda S; Takeuchi M; Tanaka Y; Ueda N; Sekiguchi S; Ishige T; Shima K; Nabeno M; Abe Y; Anabuki J; Soejima A; Yoshida K; Takashina Y; Ishii S; Kiuchi S; Fukuda S; Tsutsumiuchi R; Kosaka K; Murozono T; Nakamaru Y; Utsumi H; Masutomi N; Kishida H; Miyaguchi I; Hayashi Y
Bioorg Med Chem; 2012 Oct; 20(19):5705-19. PubMed ID: 22959556
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
[TBL] [Abstract][Full Text] [Related]
11. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
12. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
Kim KR; Rhee SD; Kim HY; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG
Eur J Pharmacol; 2005 Jul; 518(1):63-70. PubMed ID: 16106524
[TBL] [Abstract][Full Text] [Related]
13. Anti-obesity effects of KR-66195, a synthetic DPP-IV inhibitor, in diet-induced obese mice and obese-diabetic ob/ob mice.
Lee EY; Kim YW; Oh H; Choi CS; Ahn JH; Lee BW; Kang ES; Cha BS; Lee HC
Metabolism; 2014 Jun; 63(6):793-9. PubMed ID: 24684824
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
[TBL] [Abstract][Full Text] [Related]
15. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, Biological Evaluation, and Molecular Docking of (R)-2-((8-(3-aminopiperidin-1-yl)-3-methyl-7-(3-methylbut-2-en-1-yl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)methyl)benzonitrile as Dipeptidyl Peptidase IV Inhibitors.
Ran Y; Pei H; Shao M; Chen L
Chem Biol Drug Des; 2016 Feb; 87(2):290-5. PubMed ID: 26426933
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.
Kim TE; Lim KS; Park MK; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2012 Sep; 34(9):1986-98. PubMed ID: 22943970
[TBL] [Abstract][Full Text] [Related]
19. Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients.
Retlich S; Duval V; Graefe-Mody U; Jaehde U; Staab A
J Clin Pharmacol; 2010 Aug; 50(8):873-85. PubMed ID: 20160157
[TBL] [Abstract][Full Text] [Related]
20. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
